ReviewOne health (Amsterdam, Netherlands)2026
Nipah virus preparedness in a One Health framework: Implications for Europe.
Review in One health (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nipah virus (NiV) is a highly pathogenic zoonotic henipavirus associated with severe neurological and respiratory disease and a high case fatality rate. Although outbreaks have remained geographically limited, recurrent events in South and Southeast Asia highlight the persistent risk posed by NiV and the potential global consequences of delayed detection and response. In non-endemic regions such as Europe, preparedness presents distinct challenges due to the rarity of cases, stringent biosafety requirements, and reliance on specialised diagnostic and clinical capacities that may degrade without routine use. This narrative review synthesises evidence from peer-reviewed literature and international public health agency reports on NiV biology, epidemiology, diagnostics, treatment, and preparedness, with a particular focus on operational implications for Europe within a One Health framework. We examine determinants of zoonotic spillover and limited human-to-human transmission, outline constraints across the diagnostic pathway including specimen handling and biosafety requirements and summarise current approaches to clinical management and investigational medical countermeasures. Attention is given to how these factors inform risk assessment, diagnostic readiness, and clinical recognition in non-endemic health systems. Preparedness for NiV should be conceptualised as a continuous process of biomonitoring and response rather than an episodic emergency activity. Integrated surveillance across human, animal, and environmental domains is essential for early identification of spillover signals and proportionate public health action. For Europe, sustained preparedness depends on maintaining functional capacity across laboratory networks, clinical services, and public health systems, supported by cross-border coordination and the systematic integration of One Health intelligence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.